Form 4: Alto Neuroscience CEO Amit Etkin Acquires 215,000 Stock Options
SEC Form 4 Filing
CEO of Alto Neuroscience, Amit Etkin, reports the acquisition of 215,000 employee stock options.
Summary
- Amit Etkin, the President and CEO of Alto Neuroscience, Inc., filed a Form 4 on February 7, 2025.
- The filing reports the acquisition of 215,000 employee stock options on February 5, 2025, with an exercise price of $4.2.
- These options vest over time, with 25% vesting on February 5, 2026, and the remainder vesting monthly until February 4, 2035, contingent upon continuous service.
- The reporting person directly owns 215,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The acquisition of stock options by the CEO is generally seen as a positive sign, indicating confidence in the company's future performance. The vesting schedule further reinforces this positive sentiment by incentivizing long-term commitment.
Positives
- The CEO's acquisition of stock options aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment from the CEO.
Future Outlook
The vesting schedule suggests a long-term commitment from the CEO to the company's success.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- Vesting schedules are common to incentivize long-term commitment.
- The specific terms of the options (exercise price, vesting schedule) would need to be compared to similar companies in the biotechnology industry to assess their competitiveness.
Stakeholder Impact
- Shareholders may view the CEO's stock option acquisition positively, as it aligns his interests with theirs.
- Employees may see it as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of transaction: Acquisition of employee stock options. |
| 02/05/2026 | 25% of the shares underlying the option shall vest. |
| 02/04/2035 | Expiration date of the employee stock options. |
| 02/07/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.